News

Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study

NICE said in draft guidance that the breast cancer drug pertuzumab could not be recommended to treat HER2-positive breast cancer due to uncertainties over its long-term health benefits.

New Mexico-based PaizaBio will provide these services to JHL through its Hangzhou, China-based strategic partner, Ausia BioTech. The agreement is the first between JHL Biotech, which has deep

The $280 million project adds two new buildings to the 89-acre Devens campus: a Biologics Development Building for designing processes for the early production of investigational medicines, and

MONALEESA-2 is a pivotal Phase III trial of LEE011 (ribociclib), a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole, compared to letrozole alone in postmenopausal women who

Noyada is an oral liquid version of captopril used in the treatment of paediatric chronic heart failure. Cevidra Laboratories, a French-based pharmaceutical company which specialises in ATU programmes

The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial. This marks an important next step in the development

"Dosing the first patient in our Phase 3 program is an important milestone for RDD Pharma in the development of our lead product candidate," said Jason Laufer, CEO

The announcement is part of a 2016 multimillion-dollar capital investment in instrumentation, which comes in the wake of ABC’s acquisition by California-based EAG in July of last year.